Pill vaccines, infant antibodies: inside Vaxart’s 2025 shift to profit COVID pill trial milestones in 2026 and new norovirus infant data frame Vaxart’s 2025 results: $237.3M revenue, $16.3M income and runway into Q2 2027.

#VXRT Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

www.stocktitan.net/news/VXRT/vaxart-provide...

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants Vaxart (OTCQX: VXRT) published Phase 1, double-blind, placebo-controlled data showing a single-dose oral bivalent norovirus vaccine was safe and well-tolerated in lactating women and induced norovirus-specific antibodies in serum and breast milk.The study reported norovirus-specific IgA in breastfed infants' stool that correlated with breast milk IgA, suggesting passive transfer of mucosal immunity to infants. Results were published in npj Vaccines on Jan 15, 2026.

#VXRT Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

www.stocktitan.net/news/VXRT/vaxart-publish...

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results Vaxart (OTCQX: VXRT) reported Q3 2025 results and a business update on Nov 13, 2025. Key items: an exclusive license and collaboration with Dynavax for the oral COVID-19 pill vaccine (upfront $25M plus $5M equity; potential cumulative proceeds up to $700M plus royalties); completion of enrollment of ~5,400 participants in the Phase 2b COVID-19 trial with topline data expected in late 2026 and a 400-person sentinel cohort readout expected in Q1 2026.Financials: $28.8M cash/investments as of Sept 30, 2025 and runway into Q2 2027; Q3 revenue $72.4M; R&D expense $75.9M; net loss $8.1M.

#VXRT Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/VXRT/vaxart-provide...

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.

#DVAX #VXRT Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

www.stocktitan.net/news/DVAX/dynavax-report...

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.

#DVAX #VXRT Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

www.stocktitan.net/news/DVAX/dynavax-enters...

25-Fold Immune Boost: Vaxart's Pill-Based Norovirus Vaccine Could Target $10B US Market Impact Vaxart's second-gen norovirus vaccine pill shows 25x fecal IgA increase vs 13x in first-gen. Targets $10B US market impact. Phase 2 trial planned for late 2025 pending funding.

#VXRT Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

www.stocktitan.net/news/VXRT/vaxart-reports...

Critical Nasdaq Compliance Extension: Vaxart Given 7-Week Timeline to Execute Reverse Split Plan Biotech firm Vaxart must complete reverse stock split by Oct 6 and meet minimum bid requirements by Oct 17 to maintain Nasdaq listing. Shareholder vote scheduled for Sept 5.

#VXRT Vaxart Granted Extension by Nasdaq to Regain Compliance

www.stocktitan.net/news/VXRT/vaxart-granted...

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results Vaxart (OTCQX: VXRT) reported Q2 2025 financial results and provided significant updates across its vaccine pipeline. The company reported revenue of $39.7M (vs $6.4M in Q2 2024) and a net loss of $15.0M. Key developments include positive topline data from their second-generation norovirus vaccine trial, showing statistically significant increases in blocking antibodies (141% for GI.1 and 94% for GII.4) compared to first-generation constructs.The company's COVID-19 Phase 2b trial enrolled approximately 5,000 participants before receiving a stop work order, with follow-up continuing for all dosed participants. Vaxart ended Q2 with $26.3M in cash and equivalents, projecting runway into 2026. The company will hold a special stockholder meeting on September 5, 2025, to vote on a potential reverse stock split to regain Nasdaq compliance.

#VXRT Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/VXRT/vaxart-provide...

Vaxart CEO Reveals Critical Nasdaq Strategy and Pipeline Progress: Stockholders Face Major Decision CEO outlines strategic path to Nasdaq relisting, updates on 5,000-patient COVID trial progress, and extends cash runway to 2026. Get complete details.

#VXRT Vaxart CEO Issues Letter to Stockholders

www.stocktitan.net/news/VXRT/vaxart-ceo-iss...

Vaxart Fights Nasdaq Delisting: Proposes 1-for-20 Reverse Split, Crucial Hearing Set for August Critical stockholder vote on September 5 to decide Vaxart's Nasdaq future. Proposed 1:5 to 1:20 reverse split ratio. Learn how this impacts your investment. See details.

#VXRT Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

www.stocktitan.net/news/VXRT/vaxart-submits...

Vaxart Moves to OTCQX Best Market While Fighting Nasdaq Delisting - What Investors Should Know Vaxart secures spot on premium OTCQX Market while appealing Nasdaq delisting. Trading continues under VXRT symbol. Learn what this means for shareholders.

#VXRT Vaxart Announces Trading on OTCQX Best Market

www.stocktitan.net/news/VXRT/vaxart-announc...

Vaxart Faces Nasdaq Challenge as Shareholders Block Reverse Split Proposal at Annual Meeting Key votes reveal shareholders oppose management on reverse split and executive pay. See what this means for Vaxart's Nasdaq listing status. Get insights.

#VXRT Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

www.stocktitan.net/news/VXRT/vaxart-announc...

Smiling female doctor holding a small white pill capsule between her fingers, representing Vaxart Inc.'s oral vaccine development.

#VXRT is making strides in oral vaccine innovation!
New data from its Phase 1 study shows that the second-generation norovirus vaccine candidate produced stronger immune responses than the original version.
#Vaxart
prismmarketview.com/vaxarts-seco...

Vaxart Gets ISS and Glass Lewis Backing for Crucial Nasdaq Listing Vote as Deadline Nears Leading proxy firms ISS and Glass Lewis endorse Vaxart's reverse split proposal to maintain Nasdaq listing. CEO reports increasing stockholder support. See voting details.

#VXRT Vaxart Announces Adjournment of Annual Meeting of Stockholders

www.stocktitan.net/news/VXRT/vaxart-announc...

Vaxart Founder Makes Urgent Appeal: Critical Nasdaq Compliance Vote Deadline Approaches Vaxart's CSO addresses key misconceptions about reverse split proposal to maintain Nasdaq listing. Stockholders must vote by June 1. See official guidance.

#VXRT Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

www.stocktitan.net/news/VXRT/vaxart-s-found...

Vaxart Answers Additional Frequently Asked Questions from Retail Investors Vaxart (VXRT) has provided detailed responses to stockholder questions ahead of its June 2, 2025 Annual Meeting, focusing on the crucial reverse stock split proposal. The company faces a June 30, 2025 Nasdaq compliance deadline and needs stockholder approval to maintain its listing. Key points include: the Board's commitment to a maximum 1-for-20 reverse split ratio (reduced from 1-for-50), plans to proportionally reduce authorized shares, and clarification on the $460.7 million BARDA Project NextGen award structure. The company has extended voting until June 1, 2025 at 11:59 p.m. ET. Management addressed concerns about dilution, short selling, and communication transparency, while emphasizing that the reverse split is currently the primary strategy for maintaining Nasdaq listing.

#VXRT Vaxart Answers Additional Frequently Asked Questions from Retail Investors

www.stocktitan.net/news/VXRT/vaxart-answers...

Breakthrough Oral COVID Vaccine Pill Advances: Vaxart Launches Massive 10,000-Patient Trial with $460M Backing Vaxart's oral COVID-19 pill vaccine enters crucial Phase 2b trial with 10,000 participants. Government backs development with $460.7M funding. See trial details.

#VXRT Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

www.stocktitan.net/news/VXRT/vaxart-initiat...

Vaxart Announces Adjournment of Annual Meeting of Stockholders Vaxart (NASDAQ: VXRT) has announced the adjournment of its 2025 annual stockholders meeting to June 2, 2025 at 8:30 a.m. Pacific Time. The virtual meeting will address all proposals from the proxy statement filed on April 10, 2025. The company is particularly focused on gaining stockholder approval for Proposal No. 2 regarding a Reverse Stock Split, which aims to regain Nasdaq compliance for minimum bid price requirements. The Board argues this split would help maintain Nasdaq listing, increase broker/analyst coverage, attract institutional investors, and aid in employee retention. Stockholders of record as of March 26, 2025, can vote until June 1, 2025 at 11:59 p.m. Eastern Time.

#VXRT Vaxart Announces Adjournment of Annual Meeting of Stockholders

www.stocktitan.net/news/VXRT/vaxart-announc...

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting Vaxart (VXRT) has announced important amendments to its proxy statement for the upcoming Annual Meeting. The board has approved two key changes contingent on the passage of Proposal #2: limiting the reverse stock split ratio to no more than 1-for-20 and proposing to proportionally reduce the authorized number of common stock shares at a future special stockholder meeting. These changes come as Vaxart faces potential Nasdaq delisting and seeks stockholder approval for the reverse split to maintain its listing status. Leading proxy advisory firms ISS and Glass Lewis support Proposal #2. The company emphasizes that maintaining Nasdaq listing is crucial for stockholder liquidity and institutional investment accessibility. Stockholders can vote on Proposal #2 until May 20, 2025, at 11:59 p.m. ET, with previously cast negative votes eligible for change.

#VXRT Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

www.stocktitan.net/news/VXRT/vaxart-approve...

Revolutionary Oral COVID Pill Vaccine Gets $460M BARDA Backing for Massive 10,000-Patient Trial Vaxart's innovative oral COVID-19 pill vaccine secures crucial BARDA approval for expanded Phase 2b trial. Government commits $460M in funding. See trial details.

#VXRT Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

www.stocktitan.net/news/VXRT/vaxart-receive...

Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial First-ever oral pill vaccine demonstrates significant protection against norovirus infection in Phase 2b study. Key efficacy metrics exceed expectations. See full results.

#VXRT Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

www.stocktitan.net/news/VXRT/vaxart-publish...

Vaxart Unlocks $460M COVID Vaccine Trial Funding, Reports Strong Pipeline Progress in Q1 2025 COVID trial resumes with $460M potential funding, norovirus vaccine trial fully enrolled, and 100% success in avian flu study. Q1 earnings reveal $41.9M cash position.

#VXRT Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/VXRT/vaxart-provide...

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement Vaxart (VXRT) is addressing stockholder questions regarding a proposed reverse stock split ahead of its Annual Meeting on May 21, 2025. The company is seeking stockholder approval to implement a reverse split ratio between 1-for-5 and 1-for-50 to regain Nasdaq compliance, as its current share price of $0.42 (as of May 9, 2025) falls below the required $1.00 minimum bid price.The company emphasizes that the reverse split won't change stockholders' investment value or cause dilution, but will result in fewer shares at a higher price. Both leading proxy advisory firms, ISS and Glass Lewis, support the proposal. Management stresses that maintaining Nasdaq listing is crucial for market visibility, trading volume, and future financing opportunities to advance their clinical programs for COVID-19 and norovirus.The board intends to select a ratio just high enough to resolve the Nasdaq deficiency, with no current plans to implement the maximum 1:50 ratio.

#VXRT Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

www.stocktitan.net/news/VXRT/vaxart-address...

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress Vaxart (VXRT) CEO Steven Lo issued a letter to stockholders highlighting recent developments and urging support for a reverse stock split proposal. Key updates include: the lifting of a government stop work order on April 24, 2025, allowing continuation of their COVID-19 vaccine clinical trial and potential BARDA funding. The company has completed enrollment of 60 participants in their norovirus program, with topline data expected mid-2025. Vaxart implemented strategic cost reductions, including workforce cuts, extending cash runway into 2026. The company seeks stockholder approval for a potential reverse stock split at the May 21, 2025 annual meeting to maintain Nasdaq listing compliance ($1.00 minimum bid requirement). Leading proxy advisors ISS and Glass Lewis recommend voting "FOR" the proposal. Management emphasizes they will only implement the split if necessary to avoid delisting.

#VXRT Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

www.stocktitan.net/news/VXRT/vaxart-ceo-iss...

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate Vaxart has completed enrollment in its Phase 1 clinical trial comparing second-generation and first-generation oral norovirus vaccine constructs. The company expects to release topline data in mid-2025. The open-label, dose-ranging study will evaluate safety and immune parameters that previously correlated with protection in a completed norovirus challenge study. A Data and Safety Monitoring Board has reviewed interim safety data and recommended continuing the study without modifications. CEO Steven Lo emphasized the significant unmet need for a norovirus vaccine, expressing optimism about the potential increased potency of their second-generation constructs. Pending successful Phase 1 results and securing partnership or funding, Vaxart plans to: Launch Phase 2 safety and immunogenicity study in late 2025 Hold End of Phase 2 meeting with FDA Potentially begin Phase 3 trials in 2026

#VXRT Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

www.stocktitan.net/news/VXRT/vaxart-complet...

Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches Vaxart's revenue surges to $28.7M while advancing oral vaccine pipeline. Phase 1 norovirus trial initiated with data due mid-2025. $51.7M cash extends operations through Q4 2025.

#VXRT Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

www.stocktitan.net/news/VXRT/vaxart-provide...

First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach Vaxart advances novel oral pill vaccine against norovirus, targeting massive unmet need with no approved vaccines. Phase 1 trial compares next-gen formulation with data expected mid-2025.

#VXRT Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

www.stocktitan.net/news/VXRT/vaxart-announc...

Can Vaxart's Oral Norovirus Vaccine Overcome Age-Related Immune Challenges? New Data Says Yes Elderly adults showed robust antibody responses across all dose levels with Vaxart's oral norovirus vaccine, challenging the notion that older populations respond poorly to vaccines.

#VXRT Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

www.stocktitan.net/news/VXRT/vaxart-announc...

Vaxart, Inc. –Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.

#vxrt

Time to check in on Vaxart ...successful H5N1 trials in 2013 and 2019...Vaxart has the solution you are searching! "100% of the animals survived"

investors.vaxart.com/news-release...